Pidacmeran

匹达卡米瑞

Report date: 2026/05/12 09:17:28

Base Information

Drug NamePidacmeran
Drug Alias NameBNT162c2
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > self-amplifying RNA vaccine > self-amplifying mRNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsRNA Virus Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesBiontech Se
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsRNA Virus Infections +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A